BCL2L1 and acute myeloid leukemia: Yet, unlike reported in AML cells [66, 67], venetoclax did not suppress OxPhos activity in B‐cells, indicating that it did not directly enhance the inhibitory action of IACS‐010759 on ETC complex I. At the mechanistic level, and as described in other contexts [61, 62], MycER activation suppressed expression of BCL2 and Bcl‐xL.